Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer

Publication Date: May 1, 2020
Last Updated: March 14, 2022

Recommendations

Having trouble viewing table?
Hormone Therapy in Gynecologic Cancer Survivors
Uterine cancer
Early stage endometrial cancer HT acceptable
Advanced stage endometrial cancer HT not recommended
Uterine sarcoma HT not recommended
Ovarian cancer
High grade serous ovarian cancer HT acceptable
Low grade serous and endometrioid ovarian cancer HT not recommended
Cervical cancer HT acceptable
Hormone Therapy in Women at High Risk for Developing Gynecologic Cancer
BRCA mutation with no personal history of breast cancer HT acceptable
BRCA mutation with personal history of breast cancer HT not recommended
Lynch syndrome HT acceptable

Overview

Title

Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer

Authoring Organization